#Avastin

Keytruda plus chemotherapy reduced the risk of death by about 40% for people with persistent, recurrent or metastatic cervical cancer.

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

People with left-sided tumors treated with Vectibix plus standard chemotherapy had an 18% lower risk of death.

Immunotherapy plus chemotherapy improved overall survival in people with persistent, recurrent or metastatic cervical cancer.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

The combination improved both overall survival and patient-reported outcomes.

Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.

These drugs, made from living organisms, are big moneymakers partly because they have little competition. It’s a different story in Europe.